Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pentoxifylline+Tocopherol

Phase 2Small molecule

UUniversity Hospital, Limoges

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Medication-Related Osteonecrosis of the JawRecruiting

Medication-Related Osteonecrosis of the JawPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Medication-Related Osteonecrosis of the Jaw

NCT05795647

Clinical

Trials by Indication[1]

Medication-related Osteonecrosis of the Jaw1 trial

The PENTO Protocol in Medication-related Osteonecrosis of the Jaw

Recruiting·UUniversity Hospital, Limoges·Phase 2·NCT05795647·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pentoxifylline+Tocopherol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentoxifylline+Tocopherol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentoxifylline+Tocopherol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Limoges company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Limoges

Related News